Evidence map›Paper›PMID 34155273›Full record

ArticleScientific reports2021

High fructose and streptozotocin induced diabetic impairments are mitigated by Indirubin-3-hydrazone via downregulation of PKR pathway in Wistar rats.

Mary Priyanka Udumula, Sureshbabu Mangali, Jaspreet Kalra, Deepika Dasari, Srashti Goyal, Vandana Krishna, Srivarsha Reddy Bollareddy, Dharamrajan Sriram, Arti Dhar, Audesh Bhat

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Experimental models in diabetes research.Laboratory animal research · 2026
    Review
  2. International journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Anti-diabetic activity of aqueous extract ofJournal of traditional and complementary medicine · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. The Aqueous Extract ofEvidence-based complementary and alternative medicine : eCAM · 2023
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mary Priyanka Udumula *Department of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Sureshbabu Mangali *Department of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Jaspreet KalraDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Deepika DasariDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Srashti GoyalDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Vandana KrishnaDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Srivarsha Reddy BollareddyDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Dharamrajan SriramDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India.
Arti DharDepartment of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, Andhra Pradesh, 500078, India. artidhar@hyderabad.bits-pilani.ac.in.
Audesh BhatCentre for Molecular Biology, Central University of Jammu, Jammu, UT of Jammu and Kashmir, 184311, India. abhat@cujammu.ac.in.
Birla Institute of Technology and Science - Hyderabad Campus · INCentral University of Jammu · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic disorders are becoming more common in young population due to increased consumption of carbohydrate rich diet, lack of physical activity and stress. Fructose is used as a sweetener in many carbonated beverages and is a known inducer of oxidative stress and hypertension. Up-regulation of the double-stranded RNA-dependent protein kinase (PKR) causes impairment in insulin signaling pathway and metabolic dysfunctions in type 2 diabetes mellitus. In the present study we investigated the role of PKR and associated pathways in high fructose (HF) and streptozotocin (STZ) induced diabetes and whether indirubin-3-hydrazone (IHZ), a novel PKR inhibitor can reverse the HF and STZ induced diabetic impairments in Wistar rats. Diabetes was induced by feeding rats 20% high fructose in drinking water for 6 weeks and by giving a single dose of STZ (35 mg/kg., i.p) at the end of week 5. Glucose and lipid levels were measured by using assay kits. Expression of PKR and its downstream genes were determined by immunohistochemistry, qRT-PCR and western blotting techniques. Histo-pathological studies were performed using H&E staining. Fibrosis was detected in insulin sensitive tissues and organs using Sirius red and Masson's trichrome staining and apoptosis by TUNEL assay. HF and STZ induced hyperglycemia, fibrosis, oxidative stress, and inflammation in liver, pancreas, skeletal muscle and adipose tissue are mediated via PKR pathway and its downstream effectors, and these effects were attenuated by PKR inhibitor IHZ. Thus, inhibition of PKR can protect insulin sensitive organs and tissues from HF induced diabetic impairments via the inhibition of c-Jun N-terminal kinase (JNK) pathway.

Indexed as

Adipose TissueAnimalsApoptosisDiabetes Mellitus, ExperimentaleIF-2 KinaseEnergy MetabolismFibrosisFructoseIndolesMAP Kinase Signaling SystemMuscle, SkeletalOxidative StressPancreasRatsRats, WistarSignal TransductioneIF-2 KinaseFructoseindirubinIndolesStreptozocin

Identifiers

PMID34155273
PMCPMC8217483
OpenAlexW3166893944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.